Though a bankruptcy court will have the final say, Aradigm Corp., of Newark, Calif., entered a purchase agreement to sell its assets and intellectual property to Grifols SA, of Barcelona, Spain. The assets and intellectual property revolve around Lipquin, Free Ciproflaxin, Apulmiq and all their derivatives. The purchased assets will be sold free and clear of liens, claims and encumbrances, the companies said. The sale excludes Aradigm's cash and cash equivalents, accounts or notes receivable, certain contracts, tangible personal property, the company name, its accounts and records, all benefit plans and company shares. The purchase price is $3.2 million cash payable at closing; waiver of proof of claim No. 4 for $19.95 million filed by Grifols in Aradigm's bankruptcy case; waiver of proof of claim No. 5 for $11.8 million filed by Grifols’ affiliate in the bankruptcy case; a milestone payment of $2 million payable upon approval of any Aradigm product by the FDA; a milestone payment of $1 million payable upon approval of any Aradigm product by the EMA; and, during the royalty term, Aradigm will receive 25% of any royalties received by Grifols. Aradigm filed for bankruptcy protection in February 2019, a month after the company received a complete response letter for Linhaliq, to treat noncystic fibrosis bronchiectasis chronic lung infections with Pseudomonas aeruginosa. Citing inconsistent efficacy data and concern over pivotal trial endpoints, FDA advisors voted it down.
Fresh data from Toronto’s Arch Biopartners Inc. show the synergistic effects of acidified sodium nitrite and ethylenediaminetetraacetic acid (the active ingredients of AB-569) on destroying all bacteria tested as well as identifying bacterial properties that confer susceptibility to the drug. The FDA granted Arch orphan drug designation for the combination of the two active ingredients of AB-569 for treating Pseudomonas aeruginosa lung infections in patients with cystic fibrosis. The EMA granted Arch orphan medicinal status for the active ingredients to treat cystic fibrosis.
Cyclica Inc., of Toronto, said it identified and validated an active, selective sirtuin 2 inhibitor. Cyclica released a case study showing its ligand design platform for finding binders to a panel of protein targets identified 22 molecules from a commercial library of 100,000 compounds. The company then purchased them and tested them in vitro. The platform identified molecules that were active, selective and chemically distinct from known binders, including a selective hit for sirtuin 2, CYC-1858.
Erytech Pharma SA, of Lyon, France, is partnering with the German Red Cross Blood Donor Service to supply donor red blood cells to manufacture product candidates, including eryaspase, in Europe. The donor service supplies blood products for about 30 million Germans. That complements Erytech’s existing alliance with the French Etablissement Francais du Sang, which remains the primary source of supply of donor red blood cells for Erytech’s product candidates manufactured in Lyon.
Beijing’s Genetron Health Co. Ltd. and Beijing Innocare Pharma Tech Co. Ltd. will partner to provide clinical trial genomic testing and companion diagnostics development services for Innocare’s biomarker-driven oncology drug development. Genetron specializes in cancer molecular profiling.